ERBB2 and gastric cancer: CLDN18.2 was detected in 74.4% of primary gastric cancer specimens (n = 367), with roughly 29.4% meeting positivity criteria defined as moderate-to-strong immunohistochemical staining in ≥40% of tumor cells; expression is particularly enriched in diffuse-type and HER2-positive tumors [29].